Meeting
2022 ASCO Annual Meeting
Phase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable (MSS), BRAFV600E metastatic colorectal cancer.
Authors
Van K. Morris II
The University of Texas MD Anderson Cancer Center, Houston, TX
Van K. Morris II, Christine Megerdichian Parseghian , Michelle Escano , Benny Johnson , Kanwal Pratap Singh Raghav , Arvind Dasari , Ryan Huey , Michael J. Overman , Jason Willis , Michael Sangmin Lee , Robert A. Wolff , Bryan K. Kee , Phat Le , Cori Margain , Dave Gallup , Alda Tam , Wai Chin Foo , Lianchun Xiao , Kyuson Yun , Scott Kopetz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Clinical Trial Registration Number
NCT04017650
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 3598)
DOI
10.1200/JCO.2022.40.16_suppl.3598
Abstract #
3598
Poster Bd #
392
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Phase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable, BRAFV600E metastatic colorectal cancer.
First Author: Van K. Morris II
Poster
2022 ASCO Gastrointestinal Cancers Symposium
BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cet) ± chemotherapy for first-line treatment (tx) of BRAF V600E-mutant (BRAFV600) metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz
Poster
2021 ASCO Annual Meeting
BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cetux) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAFV600E) metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz
Poster
2023 ASCO Gastrointestinal Cancers Symposium
BAYONET trial: A multicenter phase II trial of staged combination with encorafenib + binimetinib + cetuximab following encorafenib + cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer.
First Author: Yuki Matsubara